

ARANTZA MURIANA MIRALLES



SHORT CURRUCULUM VITAE

MSc in Pharmacy and master's degree in R+D+i of New Drugs at the Navarra University (Pamplona, Spain), with doctorate course in Design, Synthesis, and Evaluation of New drugs, in Pharmaceutical and Organic Chemistry. Afterward, she did an MBA from the San Pablo CEU University of Madrid (Spain), where she improved her management and business development skills, and the Entrepreneurship Start Smart Course of the MIT (USA).

She began working in CRO's 18 years ago, first in the field of Clinical Trials to later in 2006 move to the pre-clinical field starting to work in Biobide SL, after a training period working with zebrafish in the Salk Institute of California (USA). During those years she had various positions in Biobide, from Quality, Safety, and Environment Director, to I.P. and Business Development Director, leading to generate a deep understanding of the zebrafish services developed in the field, and learning management skills been part of the Board of Directors. In 2013, she became co-founder of BBD BioPhenix SL to keep working on the zebrafish alternative model, offering services to Pharmaceutical companies and managing the R&D of the company to get to other markets such as the Chemical, Tobacco, or Cosmetic industries.

Nowadays she is the Chief Investigational Officer (CIO) and Chief Executive Officer (CEO) of the American affiliate office of BBD BioPhenix, where she has managed developing multiple toxicity and efficacy assay on zebrafish larvae and adults, in different areas, such as developmental, neuro, cardiovascular, immune, or endocrine disruption.

She is an invited teacher of the Master's degree in R+D+i of New Drugs at the Navarra University (Spain), Chair of the Advisory Board Committee of the Pharmaceutical Faculty of Navarra University (Spain), Mentor and Judge of MassChallenge and other associations related to Health and Entrepreneurship.

Besides she is a board member of the European Teratology Society (ETS), co-managing the Zebrafish Specialty Group; and a member of the editorial board of Reproductive Toxicology.

For further information on publications and projects see her research gate page below:

https://www.researchgate.net/profile/Arantza_Muriana/